University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Early (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy

Simple item page
dc.contributor.authorMackenzie, Scott C
dc.contributor.authorMoakes, Catherine A
dc.contributor.authorDoust, Ann M
dc.contributor.authorMol, Ben W
dc.contributor.authorDuncan, W Colin
dc.contributor.authorTong, Stephen
dc.contributor.authorHorne, Andrew W
dc.contributor.authorWhitaker, Lucy H R
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Women’s Health Researchen
dc.date.accessioned2023-06-19T14:36:01Z
dc.date.available2023-06-19T14:36:01Z
dc.date.issued2023-07
dc.descriptionAcknowledgements S.C.M. was supported by the South-East Scotland Academic Foundation Programme. Medical Research Council (MRC) Centre grants to the Centre for Reproductive Health (CRH) (G1002033 and MR/N022556/1) are also gratefully acknowledged. Funding This project was supported by funding from the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership (grant reference number 14/150/03). A.W.H. has received honoraria for consultancy for Ferring, Roche, Nordic Pharma and AbbVie. W.C.D. has received honoraria from Merck and Guerbet and research funding from Galvani Biosciences. L.H.R.W. has received research funding from Roche Diagnostics. B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). B.W.M. also reports consultancy for ObsEva and Merck and travel support from Merck. The other authors declare no competing interests.en
dc.description.statusPeer revieweden
dc.format.extent7
dc.format.extent729929
dc.identifier254608528
dc.identifier34a79501-5eda-416f-973a-7dc6a2f674e1
dc.identifier37178269
dc.identifier85163961454
dc.identifier.citationMackenzie, S C, Moakes, C A, Doust, A M, Mol, B W, Duncan, W C, Tong, S, Horne, A W & Whitaker, L H R 2023, 'Early (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy', Human reproduction (Oxford, England), vol. 38, no. 7, pp. 1261-1267. https://doi.org/10.1093/humrep/dead089en
dc.identifier.doi10.1093/humrep/dead089
dc.identifier.iss7en
dc.identifier.issn0268-1161
dc.identifier.otherunpaywall: 10.1093/humrep/dead089
dc.identifier.urihttps://hdl.handle.net/2164/20917
dc.identifier.vol38en
dc.language.isoeng
dc.relation.ispartofHuman reproduction (Oxford, England)en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjecttubal extopic pregnancyen
dc.subjectmethotrexateen
dc.subjectHuman chorionic gonadotrophinen
dc.subjectbiomarkeren
dc.subjecttreatment successen
dc.subjectProspective Studiesen
dc.subjectHumansen
dc.subjectPregnancy, Tubal/drug therapyen
dc.subjectTreatment Outcomeen
dc.subjectPregnancyen
dc.subjectFemaleen
dc.subjectRetrospective Studiesen
dc.subjectMethotrexate/therapeutic useen
dc.subjectRG Gynecology and obstetricsen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject14/150/03en
dc.subjectMedical Research Council (MRC)en
dc.subject14/150/03en
dc.subjectG1002033en
dc.subjectMR/N022556/1en
dc.subjectSupplementary Dataen
dc.subject.lccRGen
dc.titleEarly (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancyen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mackenzie_etal_HR_Early_post_treatment_Serum_VOR.pdf
Size:
712.82 KB
Format:
Adobe Portable Document Format
Download

Collections

All research